Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases (IRMtests)

Caen University Hospital

Status

Enrolling

Conditions

Memory Disorders

Treatments

Other: MRI sequences testing

Study type

Interventional

Funder types

Other

Identifiers

NCT05929144

2023-A00398-37 (Registry Identifier)

23-0030

Details and patient eligibility

About

The Inserm NeuroPresage team has been using MRI for more than 20 years in the study of normal ageing and memory pathologies to further the understanding and the characterization of early diagnosis and the cerebral substrates of cognitive deficits in patients, particularly in the context of neurodegenerative diseases.

Two years ago, a new 3T MRI camera was installed at the Cyceron centre. It is more efficient and should make it possible to obtain better quality images and/or to reduce the time required to acquire these images.

In this context, it seems important to test the different sequences that we classically use in our studies, or that we plan to implement in our next studies (learning and text retrieval fMRI task), in order to optimize them, with a view to integrating them in our future studies.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy volunteers of legal age
Affiliation with a social security scheme or beneficiary of such a scheme
Signing of the protocol informed consent
For women of childbearing age or capacity, a urine pregnancy test before inclusion

Exclusion criteria

Protected persons in accordance with articles L. 1121-5 to L.1121-8 of the Public Health Code: protected adults, pregnant and nursing women
Presence of contraindications to MRI examination without contrast agents injection
Presence of a chronic neurological or psychiatric condition (including substance use disorder)
History of brain disease (vascular, degenerative, malformative, tumour, or head trauma with loss of consciousness for more than one hour)
Current or recent use of medications that may interfere with imaging (psychotropic drugs, antihistamines with anticholinergic action, antiparkinsonian drugs, benzodiazepines including muscle relaxants, long-term steroidal anti-inflammatory drugs, antiepileptic drugs, central painkillers)